Polaryx Therapeutics (PLYX) Stock Price, News & Analysis
What Changed
Price Move History
- Daily moves over 5%
- 69 156 sessions, February 2, 2026 to September 15, 2026
- Largest daily move
- +69.6% close of March 10, 2026
Company Description
Polaryx Therapeutics (NASDAQ: PLYX) is classified in the biotechnology industry within the Healthcare sector and carries a market capitalization of $103.2M.
PLYX has declined 21.3% over the past month. The last closing price was $2.04.
For FY2025, Polaryx Therapeutics reported net income of -$9.0M and diluted earnings per share of -$0.20.
This page collects what Stock Titan holds for PLYX, including price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
Polaryx Therapeutics (PLYX) closed at $2.04 on September 15, 2026. Over the past month, the price has lost 21.3%.
PLYX Metrics & Rankings
Price returns through September 15, 2026. Month-to-date and YTD include the first trading day. Ranking links may use different dates.
Latest News
Polaryx Therapeutics has 10 recent news articles. Of the recent coverage, 4 articles coincided with positive price movement and 6 with negative movement. Key topics include clinical trial, private placement. View all PLYX news →
SEC Filings
Polaryx Therapeutics has filed 5 recent SEC filings, including 2 Form 8-K, 1 Form 10-Q, 1 Form ARS, 1 Form DEF 14A. The most recent filing was submitted on September 11, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all PLYX SEC filings →
Financial Highlights
operating income reached -$7.8M, and net income was -$9.0M. Diluted earnings per share stood at -$0.20. The company generated -$3.9M in operating cash flow. With a current ratio of 8.55, the balance sheet reflects a strong liquidity position.
Upcoming Events
SOTERIA Phase 2 start
SOTERIA trial initiation
Polaryx Therapeutics has 2 upcoming scheduled events. The next event, "SOTERIA Phase 2 start", is scheduled for October 1, 2026 (in 14 days). Investors can track these dates to stay informed about potential catalysts that may affect the PLYX stock price.
Short Interest History
Short interest in Polaryx Therapeutics (PLYX) currently stands at 204.5 thousand shares, down 17.9% from the previous reporting period, representing 1.4% of the float. Since February 2026, short interest has increased by 681.2%. This relatively low short interest suggests limited bearish sentiment.
Days to Cover History
Days to cover for Polaryx Therapeutics (PLYX) currently stands at 1.7 days, down 34.6% from the previous period. This low days-to-cover ratio indicates high liquidity, allowing short sellers to quickly exit positions if needed. The days to cover has increased 70% over the past year, indicating improving liquidity conditions. The ratio has shown significant volatility over the period, ranging from 1.0 to 3.8 days.
PLYX Company Profile & Sector Positioning
Polaryx Therapeutics (PLYX) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.